论文部分内容阅读
目的 建立产生人源性抗肝癌单克隆抗体的人—鼠杂交瘤。方法 用IL—2和美洲商陆(PWM)体外刺激肝癌病人外周血淋巴细胞,再与小鼠骨髓瘤细胞NS—1融合,待杂交瘤生长进行筛选、克隆化及特性分析。结果 建立了3株产生人源性抗肝癌单克隆抗体的人—鼠杂交瘤—AF3,CB7、CH1。三种单抗均识别肝癌细胞表面抗原,并具有显著的补体依赖的细胞毒活性。其中AF3的效价最高。结论 通过人—鼠杂交瘤技术获得了产生人源性抗肝癌单克隆抗体的杂交瘤细胞系。抗体效价高,是一种较理想的单克隆抗体。
Objective To establish a human-mouse hybridoma that produces human-derived anti-hepatocarcinoma monoclonal antibodies. Methods Peripheral blood lymphocytes from patients with hepatocellular carcinoma were stimulated with IL-2 and pokeweed (Principis pylori) in vitro and fused with mouse myeloma cell line NS-1. The hybridomas were selected for growth, cloned and characterized. Results Three human-mouse hybridomas--AF3, CB7 and CH1-having human monoclonal antibodies against human hepatocarcinoma were established. All three monoclonal antibodies recognize the surface antigens of liver cancer cells and have significant complement-dependent cytotoxic activity. Among them, AF3 has the highest potency. Conclusion Hybridoma cell lines producing human anti-hepatocarcinoma monoclonal antibodies were obtained by human-mouse hybridoma technology. High antibody titer is an ideal monoclonal antibody.